S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial

References

• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–810.
   PubMed Web of Science ®Google Scholar
• Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(11):1095–1103.
   PubMed Web of Science ®Google Scholar
• Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the national cancer database. J Am Coll Surg. 1999;189(1):1–7.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–277.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama. 2013;310(14):1473–1481.
   PubMed Web of Science ®Google Scholar
• Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–257.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548–557.
   PubMed Web of Science ®Google Scholar
• The Chinese Society of Clinical Oncology Pancreatic Cancer Expert Committee. Chinese expert consensus on comprehensive diagnosis and treatment of pancreatic cancer. [cited 2018 Dec 13]. Available from: http://guide.medlive.cn/guideline/14368
   Google Scholar
• Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011;102(2):478–483.
   PubMed Web of Science ®Google Scholar
• Chen HD, Zhou J, Wen F, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017;143(2):361–368.
   PubMed Web of Science ®Google Scholar
• Ohkawa S, Okusaka T, Isayama H, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2015;112(9):1428–1434.
   PubMed Web of Science ®Google Scholar
• Hernandez Alava M, Wailoo A, Grimm S, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhao R, Wen F, et al. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Med Oncol. 2015;32(4):121.
   PubMed Web of Science ®Google Scholar
• Tringale KR, Carroll KT, Zakeri K, et al. Cost-effectiveness analysis of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck. J Natl Cancer Inst. 2018;110(5):479–485.
   PubMedGoogle Scholar
• Graham CN, Hechmati G, Hjelmgren J, et al. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014;50(16):2791–2801.
   PubMed Web of Science ®Google Scholar
• Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S68–80.
   PubMed Web of Science ®Google Scholar
• Reed SD. Statistical considerations in economic evaluations: a guide for cardiologists. Eur Heart J. 2014;35(25):1652–1656.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–251.
   PubMed Web of Science ®Google Scholar
• Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol. 2014;20(41):15110–15118.
   PubMed Web of Science ®Google Scholar
• Krasniqi E, Pellicori S, Formica V. Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol. 2015;36(4):219–228.
   PubMed Web of Science ®Google Scholar
• McDonagh EM, Wassenaar C, David SP, et al. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics. 2012;22(9):695–708.
   PubMed Web of Science ®Google Scholar
• Blum MA, Suzuki A, Taketa T, et al. The role of S-1 in the treatment of gastric cancer. Gastrointest Cancer. 2011;1:59–67.
   Google Scholar
• Kurihara T, Kobayashi M, Kogo M, et al. Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer. Gan To Kagaku Ryoho. 2010;37(4):659–664.
   PubMedGoogle Scholar